It's fun to peruse the Form 13-Fs of the most successful investors. Not only can you get investment ideas, but if you’re an activist investor, you can get a sneak peek at the next company your favorite investors are planning on flexing their muscles against.
Carl Icahn recently took an initial position now worth around $200 million in Amylin Pharmaceuticals
I'm guessing Icahn will choose the latter, since selling the company seems like a difficult proposition. Amylin's present and its near-term future are both tied to its diabetes drug Byetta and a follow-on once-weekly version, both of which are partnered with Eli Lilly
It's easy to predict what Icahn's beef with management will be. Sales of Byetta have begun to stagnate, and competition from Novo Nordisk
Until the Investor of the Year nominee comes out and tells us his thinking -- after he finishes dealing with Yahoo!